-
1
-
-
0026770377
-
-
Hynes R.O. Cell. 69:1992;11.
-
(1992)
Cell
, vol.69
, pp. 11
-
-
Hynes, R.O.1
-
4
-
-
0028670833
-
-
Brooks P.C., Montgomery A.M.P., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D.A. Cell. 79:1994;1157.
-
(1994)
Cell
, vol.79
, pp. 1157
-
-
Brooks, P.C.1
Montgomery, A.M.P.2
Rosenfeld, M.3
Reisfeld, R.A.4
Hu, T.5
Klier, G.6
Cheresh, D.A.7
-
5
-
-
0028972105
-
-
Brooks P.C., Strömblad S., Klemke R., Visscher D., Sarkar F.H., Cheresh D.A. J. Clin. Invest. 96:1995;1815.
-
(1995)
J. Clin. Invest.
, vol.96
, pp. 1815
-
-
Brooks, P.C.1
Strömblad, S.2
Klemke, R.3
Visscher, D.4
Sarkar, F.H.5
Cheresh, D.A.6
-
6
-
-
0030993245
-
-
Max R., Gerritsen R.R., Nooijen P.T., Goodman S.L., Sutter A., Keilholz U., Ruiter D.J., De Waal R.M. Int. J. Cancer. 71:1997;320.
-
(1997)
Int. J. Cancer
, vol.71
, pp. 320
-
-
Max, R.1
Gerritsen, R.R.2
Nooijen, P.T.3
Goodman, S.L.4
Sutter, A.5
Keilholz, U.6
Ruiter, D.J.7
De Waal, R.M.8
-
7
-
-
0031724191
-
-
Gasparini G., Brooks P.C., Biganzoli E., Vermeulen P.B., Bonoldi E., Dirix L.Y., Ranieri G., Miceli R., Cheresh D.A. Clin. Cancer Res. 4:1998;2625.
-
(1998)
Clin. Cancer Res.
, vol.4
, pp. 2625
-
-
Gasparini, G.1
Brooks, P.C.2
Biganzoli, E.3
Vermeulen, P.B.4
Bonoldi, E.5
Dirix, L.Y.6
Ranieri, G.7
Miceli, R.8
Cheresh, D.A.9
-
8
-
-
0035158628
-
-
Vonlaufen A., Wiedle G., Borisch B., Birrer S., Luder P., Imhof B.A. Mod. Pathol. 14:2001;1126.
-
(2001)
Mod. Pathol.
, vol.14
, pp. 1126
-
-
Vonlaufen, A.1
Wiedle, G.2
Borisch, B.3
Birrer, S.4
Luder, P.5
Imhof, B.A.6
-
9
-
-
0030960689
-
-
Natali P.G., Hamby C.V., Felding-Habermann B., Liang B., Nicotra M.R., Di Filippo F., Giannarelli D., Temponi M., Ferrone S. Cancer Res. 57:1997;1554.
-
(1997)
Cancer Res.
, vol.57
, pp. 1554
-
-
Natali, P.G.1
Hamby, C.V.2
Felding-Habermann, B.3
Liang, B.4
Nicotra, M.R.5
Di Filippo, F.6
Giannarelli, D.7
Temponi, M.8
Ferrone, S.9
-
13
-
-
0042424548
-
-
Rolli M., Fransvea E., Pilch J., Saven A., Felding-Habermann B. Proc. Natl. Acad. Sci. U.S.A. 100:2003;9482.
-
(2003)
Proc. Natl. Acad. Sci. U.S.A.
, vol.100
, pp. 9482
-
-
Rolli, M.1
Fransvea, E.2
Pilch, J.3
Saven, A.4
Felding-Habermann, B.5
-
14
-
-
0031770035
-
-
Hsu M.Y., Shih D.T., Meier F.E., Van Belle P., Hsu J.Y., Elder D.E., Buck C.A., Herlyn M. Am. J. Pathol. 153:1998;1435.
-
(1998)
Am. J. Pathol.
, vol.153
, pp. 1435
-
-
Hsu, M.Y.1
Shih, D.T.2
Meier, F.E.3
Van Belle, P.4
Hsu, J.Y.5
Elder, D.E.6
Buck, C.A.7
Herlyn, M.8
-
16
-
-
4243299683
-
-
See for instance: and references cited therein
-
See for instance: Coleman P.J., Askew B.C., Hutchinson J.H., Whitman D.B., Perkins J.J., Hartman G.D., Rodan G.A., Leu C., Prueksaritanont T., Fernandez-Metzler C., Merkle K.M., Lynch R., Lynch J.J., Rodan S.B., Duggan M.E. Bioorg. Med. Chem. Lett. 12:2002;2463. and references cited therein.
-
(2002)
Bioorg. Med. Chem. Lett.
, vol.12
, pp. 2463
-
-
Coleman, P.J.1
Askew, B.C.2
Hutchinson, J.H.3
Whitman, D.B.4
Perkins, J.J.5
Hartman, G.D.6
Rodan, G.A.7
Leu, C.8
Prueksaritanont, T.9
Fernandez-Metzler, C.10
Merkle, K.M.11
Lynch, R.12
Lynch, J.J.13
Rodan, S.B.14
Duggan, M.E.15
-
17
-
-
18344375818
-
-
Lange U.E.W., Backfisch G., Delzer J., Geneste H., Graef C., Hornberger W., Kling A., Lauterbach A., Subkowski T., Zechel C. Bioorg. Med. Chem. Lett. 12:2002;1379.
-
(2002)
Bioorg. Med. Chem. Lett.
, vol.12
, pp. 1379
-
-
Lange, U.E.W.1
Backfisch, G.2
Delzer, J.3
Geneste, H.4
Graef, C.5
Hornberger, W.6
Kling, A.7
Lauterbach, A.8
Subkowski, T.9
Zechel, C.10
-
18
-
-
0035821594
-
-
Gabor S.A.G., Gibson C., Goodman S.L., Holzemann G., Wiesner M., Kessler H. J. Med. Chem. 44:2001;1938.
-
(2001)
J. Med. Chem.
, vol.44
, pp. 1938
-
-
Gabor, S.A.G.1
Gibson, C.2
Goodman, S.L.3
Holzemann, G.4
Wiesner, M.5
Kessler, H.6
-
19
-
-
0032080854
-
-
Carron C.P., Meyer D.M., Pegg J.A., Engleman V.W., Nickols M.A., Settle S.L., Westlin W.F., Ruminski P.G., Nickols G.A. Cancer Res. 58:1998;1930.
-
(1998)
Cancer Res.
, vol.58
, pp. 1930
-
-
Carron, C.P.1
Meyer, D.M.2
Pegg, J.A.3
Engleman, V.W.4
Nickols, M.A.5
Settle, S.L.6
Westlin, W.F.7
Ruminski, P.G.8
Nickols, G.A.9
-
21
-
-
85030912485
-
-
Chemical stability was measured on the final compounds, in the Tris buffer, pH 7.4, used for the biochemical assays
-
Chemical stability was measured on the final compounds, in the Tris buffer, pH 7.4, used for the biochemical assays.
-
-
-
-
22
-
-
9544258252
-
-
Binding assays were performed as described in the literature:
-
Binding assays were performed as described in the literature: Wong A., Hwang S.M., McDevitt P., McNulty D., Stadel J.M., Johanson K. Mol. Pharm. 50:1996;529.
-
(1996)
Mol. Pharm.
, vol.50
, pp. 529
-
-
Wong, A.1
Hwang, S.M.2
McDevitt, P.3
McNulty, D.4
Stadel, J.M.5
Johanson, K.6
-
23
-
-
15844420283
-
-
Briefly, the integrin was coated onto a 96-well plate (50 mg/well) and 5 nM biotinylated vitronectin was allowed to bind for 30 min at 37 °C, with or without increasing concentrations of the competing molecules. The plate was then rinsed and incubated 45 min with streptavidin conjugated to peroxidase. The amount of vitronectin bound was monitored after addition of Turbo-TMB as peroxidase substrate, and the yellow color produced was read by a Packard ELISA reader, at 450 nm wavelength. Data were analyzed using the computerized program 'GraphPad Prism'
-
Brooks P.C., Stromblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., Quigley J.P., Cheresh D.A. Cell. 85:1996;683. Briefly, the integrin was coated onto a 96-well plate (50 mg/well) and 5 nM biotinylated vitronectin was allowed to bind for 30 min at 37 °C, with or without increasing concentrations of the competing molecules. The plate was then rinsed and incubated 45 min with streptavidin conjugated to peroxidase. The amount of vitronectin bound was monitored after addition of Turbo-TMB as peroxidase substrate, and the yellow color produced was read by a Packard ELISA reader, at 450 nm wavelength. Data were analyzed using the computerized program 'GraphPad Prism'.
-
(1996)
Cell
, vol.85
, pp. 683
-
-
Brooks, P.C.1
Stromblad, S.2
Sanders, L.C.3
Von Schalscha, T.L.4
Aimes, R.T.5
Stetler-Stevenson, W.G.6
Quigley, J.P.7
Cheresh, D.A.8
-
24
-
-
85030896533
-
-
2). Then, 10 μL of adhesion medium containing inhibitors at suitable concentrations were added to test wells. 90 μL/well of cell suspension was plated and incubated for 1 h at 37 °C. Following adhesion, plates were gently washed and cells fixed with 50 μL TCA 50% (trichloroacetic acid). Evaluation of cell adhesion was performed by staining with sulforhodamine B
-
2). Then, 10 μL of adhesion medium containing inhibitors at suitable concentrations were added to test wells. 90 μL/well of cell suspension was plated and incubated for 1 h at 37 °C. Following adhesion, plates were gently washed and cells fixed with 50 μL TCA 50% (trichloroacetic acid). Evaluation of cell adhesion was performed by staining with sulforhodamine B.
-
-
-
-
25
-
-
85030891212
-
-
CEMD9 is a recombinant sub-line, derived from an acute lymphoblastic leukemia (ATCC CCL-119), stably expressing αvβ3 integrin obtained by co-transfecting cDNAs encoding human αv and β3 subunits. Cells were dispensed in 96 wells and treatment was performed 2 h later. Evaluation of growing inhibition was done 72 h later
-
CEMD9 is a recombinant sub-line, derived from an acute lymphoblastic leukemia (ATCC CCL-119), stably expressing αvβ3 integrin obtained by co-transfecting cDNAs encoding human αv and β3 subunits. Cells were dispensed in 96 wells and treatment was performed 2 h later. Evaluation of growing inhibition was done 72 h later.
-
-
-
|